Researchers Identify A New Vaccine Candidate for Chikungunya Virus

by Rukmani Krishna on  February 28, 2013 at 11:10 PM Chikungunya News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new method of vaccine creation for Chikungunya virus (CHIKV) using a technique called large scale random codon re-encoding was developed by researchers. This method has helped them modify nucleic acid composition of the virus without changing encoded viral proteins.
 Researchers Identify A New Vaccine Candidate for Chikungunya Virus
Researchers Identify A New Vaccine Candidate for Chikungunya Virus

Using this approach, a group from the UMR_D 190, Emerging viruses Department in Marseille, France in collaboration with the University of Sydney, Australia, showed that the engineered viruses exhibit a stable phenotype with a significantly decreased viral fitness (i.e., replication capacity), making it a new vaccine candidate for the emerging viral disease.

When the large-scale codon re-encoding method was applied by Antoine Nougairede and his colleagues to poliovirus and Influenza A virus, it resulted in a live but attenuated virus that had significant reduction of viral fitness.

This study demonstrates that a random approach reduced the replicative fitness of CHIKV in both primate and arthropod cells.

The strategy also prevented the reversion of the attenuated phenotype by mutation or recombination, thus reducing the possibility that the newly created virus strain could evolve back to the pathogenic version.

The findings suggest that large-scale codon re-encoding can provide a strong basis for the rapid design of next-generation viral vaccines against emerging viral pathogens, as soon as their genome sequence has been determined.

It represents another route to vaccine development as it intrinsically alleviates the likelihood of novel pathogenic properties of the designed live vaccine, and allows modulation of the amount of reduced fitness by altering the terms and degree of the genetic re-encoding.

Thus, this strategy potentially allows for the generic development of live attenuated vaccines against many new viral pathogens, with reduced costs and the potential single dose induction of long-term immunity.

This report has been published in the Open Access journal, PLOS Pathogens.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Chicken Pox Shigellosis Dengue and Homeopathy Chikungunya and Homeopathy Chikungunya Vaccination for Children Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive